Rising PSA in nonmetastatic prostate cancer

ONCOLOGY

Volumn 21, Issue 12, 2007, Pages 1436-1445

  Moul, Judd W ^a   Bañez, Lionel L ^a   Freedland, Stephen J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ALPHA REDUCTASE INHIBITOR; ANDROGEN; ANTIANDROGEN; ATRASENTAN; BICALUTAMIDE; CELECOXIB; DIETHYLSTILBESTROL; DOCETAXEL; ENZYME INHIBITOR; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; KETOCONAZOLE; NILUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RECLAST; TAMOXIFEN; UNCLASSIFIED DRUG; XINTAY; ZOLEDRONIC ACID;

BREAST TENDERNESS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOTHERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HORMONAL THERAPY; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MASTALGIA; MEN'S HEALTH; METASTASIS; MONOTHERAPY; POMEGRANATE JUICE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK FACTOR; SALVAGE THERAPY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; UROLOGY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; CRYOTHERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 37149040479     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007.
2. Greene KL, Cowan JE, Cooperberg MR, et al: Who is the average patient presenting with prostate cancer? Urology 66:76-82, 2005.
3. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001.
4. Amling CL, Bergstralh EJ, Blute ML, et al: Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146-1151, 2001.
5. Freedland SJ, Sutter ME, Dorey F, et al: Defining the ideal cutpoint for determining psa recurrence after radical prostatectomy. Urology 61:365-369, 2003.
6. Cookson MS, Aus G, Burnett AL, et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540-545, 2007.
7. Horwitz EM, Vicini FA, Ziaja EL, et al: The correlation between the ASTRO consensus panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American society of therapeutic radiology and oncology. Int J Radiat Oncol Biol Phys 41:267-272, 1998.
8. Horwitz EM, Thames HD, Kuban DA, et al: Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173:797-802, 2005.
9. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after psa elevation following radical prostatectomy. JAMA 281:1591-1597, 1999.
10. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005.
11. Freedland SJ, Humphreys EB, Mangold LA, et al: Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25:1765-1771, 2007.
12. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992.
13. Zagars GK, Pollack A: The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72:832-842, 1993.
14. Trapasso JG, deKernion JB, Smith RB, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825, 1994.
15. Ward JF, Blute ML, Slezak J, et al: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170:1872-1876, 2003.
16. Okotie OT, Aronson WJ, Wieder JA, et al: Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171:2260-2264, 2004.
17. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003.
18. D'Amico AV, Cote K, Loffredo M, et al: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20:4567-4573, 2002.
19. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997.
20. Zagars GK, Pollack A: Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997.
21. Soergel TM, Koch MO, Foster RS, et al: Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol 166:2198-2201, 2001.
22. Zhou P, Chen MH, McLeod D, et al: Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23:6992-6998, 2005.
23. Pinover WH, Horwitz EM, Hanlon AL, et al: Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97:1127-1133, 2003.
24. Slovin SF, Wilton AS, Heller G, et al: Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11:8669-8673, 2005.
25. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19:1030-1039, 2001.
26. Koppie TM, Grossfeld GD, Nudell DM, et al: Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy ? J Urol 166:111-115, 2001.
27. Katz MS, Zelefsky MJ, Venkatraman ES, et al: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21:483-489, 2003.
28. Stephenson AJ, Shariat SF, Zelefsky MJ, et al: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325-1332, 2004.
29. Anscher MS, Clough R, Dodge R: Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 48:369-375, 2000.
30. Cox JD, Gallagher MJ, Hammond EH, et al: Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American society for therapeutic radiology and oncology consensus panel. J Clin Oncol 17:1155, 1999.
31. Pazona JF, Han M, Hawkins SA, et al: Salvage radiation therapy far prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174:1282-1286, 2005.
32. Stephenson AJ, Scardino PT, Kattan MW, et al: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041, 2007.
33. Ward JF, Sebo TJ, Blute ML, et al: Salvage surgery for radiorecurrent prostate cancer. Contemporary outcomes. J Urol 173:1156-1160, 2005.
34. Bianco FJ Jr, Scardino PT, Stephenson AJ, et al: Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62:448-453, 2005.
35. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al: Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 172:2239-2243, 2004.
36. Han KR, Cohen JK, Miller RJ, et al: Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. J Urol 170:1126-1130, 2003.
37. Anastasiadis AG, Sachdev R, Salomon L, et al: Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol 129:676-682, 2003.
38. Touma NJ, Izawa JI, Chin JL: Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 173:373-379, 2005.
39. Ismail M, Ahmed S, Kastner C, et al: Salvage cryotherapy for recurrent prostate cancer after radiation failure: A prospective case series of the first 100 patients. BJU Int 100:760-764, 2007.
40. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168:9-12, 2002.
41. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 294:238-244, 2005.
42. Bayoumi AM, Brown AD, Garber AM: Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92:1731-1739, 2000.
43. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate cancer trialists' collaborative group. Lancet 355:1491-1498, 2000.
44. Klotz L, Schellhammer P: Combined androgen blockade: The case for bicalutamide. Clin Prostate Cancer 3:215-219, 2005.
45. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an american society of clinical oncology practice guideline. J Clin Oncol 25:1596-1605, 2007.
46. Byar DP, Corte DK: Hormone therapy for prostate cancer: Results of the veterans administration cooperative urological research group studies. NCI Monogr 165-170, 1988.
47. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the medical research council trial. The medical research council prostate cancer working party investigators group. Br J Urol 79:235-246, 1997.
48. Kirk D: Immediate vs deferred hormone treatment for prostate cancer. How safe is androgen deprivation? Br J Urol 86:S220, 2000.
49. Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479, 2006.
50. Moul JW, Wu H, Sun L, McLeod DG, et al: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171:1141-1147, 2004.
51. Shipley WU, Desilvio M, Pilepich MV, et al: Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of rtog protocol 86-10. Int J Radiat Oncol Biol Phys 64:1162-1167, 2006.
52. Iversen P, Tyrrell CJ, Kaisary AV, et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164:1579-1582, 2000.
53. McLeod DG, Iversen P, See WA, et al: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97:247-254, 2006.
54. Di Lorenzo G, Perdona S, De Placido S, et al: Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: The role of tamoxifen and radiotherapy. J Urol 174:2197-2203, 2005.
55. Barqawi A, Akduman B, Abouelfadel Z, et al: The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. BJU Int 92:695-698, 2003.
56. Fleshner NE, Trachtenberg J: Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal sfde effects. J Urol 154:1642-1646 (incl discussion), 2005.
57. Ornstein DK, Rao GS, Johnson B, et al: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 48:901-905, 1996.
58. Barqawi AB, Moul JW, Ziada A, et al: Combination of low-dose flutamide and finasteride for psa-only recurrent prostate cancer after primary therapy. Urology 62:872-876, 2003.
59. Bañez LL, Blake G, McLeod DG, et al: Phase II trial of combination low-dose flutamide plus finasteride versus low-dose flutamide monotherapy for biochemical recurrence following definitive therapy for prostate cancer: Long-term follow-up. Manuscript in preparation 2007.
60. Bhandari MS, Crook J, Hussain M: Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 23:8212-8218, 2005.
61. Pruthi RS, Derksen JE, Moore D, et al: Phase ii trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12:2172-2177, 2006.
62. Smith MR, Manola J, Kaufman DS, et al: Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24:2723-2728, 2006.
63. Pantuck AJ, Leppert JT, Zomorodian N, et al: Phase ii study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12:4018-4026, 2006.
64. Smith MR, Kabbinavar F, Saad F, et al: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925, 2005.
65. Schellhammer PF, Venner P, Haas GP, et al: Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157:1731-1735, 1997.
66. Kucuk O, Fisher E, Moinpour CM, et al: Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A southwest oncology group study (SWOG 9235). Urology 58:53-58, 2001.
67. Kassouf W, Tanguay S, Aprikian AG: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169:1742-1744, 2003.
68. Smith DC, Redman BG, Flaherty LE, et al: A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 52:257-260, 1998.
69. Small EJ, Baron A, Bok R: Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80:1755-1759, 1997.
70. Beer TM, Garzotto M, Eilers KM, et al: Phase ii study of abarelix depot for androgen independent prostate cancer progression during gonadotropin- releasing hormone agonist therapy. J Urol 169:1738-1741, 2003.
71. Dreicer R, Carducci M: E-1899: An eastern cooperative oncology group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. Rev Urol 5(suppl 2):S35-S41, 2003.
72. Nelson JB, Chin JL, Love W, et al: Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC) (abstract 5018). J Clin Oncol 25(18S):239s, 2007.